Insulin-like Growth Factor II mRNA-Binding Protein 3 Expression in Benign and Premalignant Lesions and Carcinomas of the Stomach. |
Dae Hyun Song, Jung Wook Yang, Dong Chul Kim, Jong Sil Lee, Jeong Hee Lee, Sang Ho Jeong, Gyung Hyuck Ko |
1Department of Pathology, Gyeongsang National University School of Medicine, Jinju, Korea. gyunghko@gnu.ac.kr 2Gyeongsang Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, Korea. 3Department of Surgery, Gyeongsang National University School of Medicine, Jinju, Korea. |
|
|
ABSTRACT |
BACKGROUND: Recent studies have demonstrated that insulin-like growth factor II mRNA-binding protein 3 (IMP3) is expressed in malignant tumors of various organs but not in normal tissue. We investigated IMP3 expression in various benign lesions, premalignant lesions and carcinomas of the stomach.
METHODS: IMP3 immunohistochemical staining was performed on 24 benign gastric lesions, 24 gastric adenomas, and 322 gastric carcinomas.
RESULTS: IMP3 was not expressed in benign gastric lesions including adenomas with low-grade dysplasia, but was expressed in 17% of adenomas with high-grade dysplasia, and in 44% of carcinomas. As the carcinomas were in the advanced stage, they expressed IMP3 more frequently and strongly.
Patients with IMP3-positive tumors had poorer survival than those with negative tumors.
CONCLUSIONS: IMP3 expression in gastric carcinoma may be related to tumor invasion and metastasis, and is an independent risk factor for poor prognosis. |
Key Words:
Stomach; Carcinoma; Adenoma; IMP3 protein |
|